Rubiamara Mauricio de Sousa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rubiamara Mauricio de Sousa has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Gabriel Araujo-Silva
Universidade do Estado do Amapá Macapá Brazil
4 shared publications - Jefferson Romáryo Duarte da Luz
Faculdade de Ciências Biológicas, Universidade Federal do Amapá (UNIFAP), Rodovia BR-156, Oiapoque 68980-000, Amapá, Brazil
4 shared publications - Maria das Graças Almeida
Multidisciplinary Research Laboratory, Department of Clinical and Toxicological Analyses, Health Sciences Center, Federal University of Rio Grande do Norte, R. Gen. Gustavo Cordeiro de Farias, s/n, Petrópolis, Natal 59012-570, RN, Brazil
4 shared publications - Saulo Victor e Silva
Laboratorio de Microencapsulación de Compuestos Bioactivos (LAMICBA), Departamento de Ciencia de los Alimentos y Nutrición, Facultad de Ciencias de la Salud, Universidad de Antofagasta, Angamos 601, Antofagasta 1240000, Chile
3 shared publications - Eder Alves Barbosa
Laboratory of Synthesis and Analysis of Biomolecules (LSAB), Institute of Chemistry, Darcy Ribeiro University Campus, University of Brasilia, Brasília 70910-900, DF, Brazil
2 shared publications - Gisele Custódio de Souza
Drug Research Laboratory, Department of Biological and Health Sciences, Universidade Federal do Amapá, Rodovia Josmar Chaves Pinto, Km 02, Macapá CEP 68903-419, AP, Brazil
2 shared publications
Latest Publications
- Open Access
Momordica charantia L. (Cucurbitaceae) Leaf Extract from Phytochemical Characterization and Toxicity Evaluation to Modulation of Pro-Inflammatory Cytokines and MAPK/NFκB Pathways
Momordica charantia L. (Cucurbitaceae) has been widely recognized for its pharmacological potential, although studies on its leaves remain scarce. In this study, the hydroethanolic leaf extract (MCHLE) was chemically characterized by LC–MS/MS, revealing the presence of octopamine, ferulate, vitexin-2-O-rhamnoside, and other bioactive phenolics. Toxicological evaluation in Wistar rats demonstrated that both acute (2000 mg/kg) and repeated oral administration (up to 400 mg/kg for 28 days) caused no clinical or behavioral signs of toxicity. Notably, treatment significantly reduced glucose and cholesterol levels, in addition to attenuating lipid peroxidation and enhancing antioxidant defenses. In vivo, MCHLE inhibited leukocyte and neutrophil infiltration in the LPS-induced peritonitis model, with efficacy comparable to dexamethasone. It also reduced TNF-α secretion and nitric oxide generation in peritoneal fluids. In vitro assays with LPS-stimulated RAW 264.7 macrophages confirmed these effects, showing dose-dependent inhibition of TNF-α, IL-1β, and NO production. Gene expression analysis further demonstrated downregulation of TNF-α and MAPK, with marked suppression of NF-κB transcripts. Collectively, these results suggest that MCHLE exerts anti-inflammatory activity by targeting both mediator release and upstream signaling pathways, while maintaining a favorable safety profile, supporting its potential for further investigation as a promising source of bioactive compounds.
Open AccessMomordica charantia L. (Cucurbitaceae) Leaf Extract from Phytochemical Characterization and Toxicity Evaluation to Modulation of Pro-Inflammatory Cytokines and MAPK/NFκB Pathways
Momordica charantia L. (Cucurbitaceae) has been widely recognized for its pharmacological potential, although studies on its leaves remain scarce. In this study, the hydroethanolic leaf extract (MCHLE) was chemically characterized by LC–MS/MS, revealing the presence of octopamine, ferulate, vitexin-2-O-rhamnoside, and other bioactive phenolics. Toxicological evaluation in Wistar rats demonstrated that both acute (2000 mg/kg) and repeated oral administration (up to 400 mg/kg for 28 days) caused no clinical or behavioral signs of toxicity. Notably, treatment significantly reduced glucose and cholesterol levels, in addition to attenuating lipid peroxidation and enhancing antioxidant defenses. In vivo, MCHLE inhibited leukocyte and neutrophil infiltration in the LPS-induced peritonitis model, with efficacy comparable to dexamethasone. It also reduced TNF-α secretion and nitric oxide generation in peritoneal fluids. In vitro assays with LPS-stimulated RAW 264.7 macrophages confirmed these effects, showing dose-dependent inhibition of TNF-α, IL-1β, and NO production. Gene expression analysis further demonstrated downregulation of TNF-α and MAPK, with marked suppression of NF-κB transcripts. Collectively, these results suggest that MCHLE exerts anti-inflammatory activity by targeting both mediator release and upstream signaling pathways, while maintaining a favorable safety profile, supporting its potential for further investigation as a promising source of bioactive compounds.
- 28 August 2025
- Published by Sociedad Chilena de Nutricion in Revista chilena de nutrición
- Vol. 52 (4) , 192-205
A preliminary study about Coenzyme Q10 and Zinc supplementation in children with Down Syndrome
Down syndrome (DS) is marked by oxidative stress due to an imbalance between reactive oxygen species (ROS) and antioxidant enzymes. Antioxidant compounds like coenzyme Q10 (CoQ10) and zinc (Zn) may mitigate cellular imbalances induced by elevated ROS levels. This double-blind, randomized clinical trial assessed the effects of CoQ10 supplementation, alone and in combination with Zn, in 20 children with DS aged 2–9 years. We evaluated biochemical parameters, dietary intake, anthropometric measures, lipid peroxidation, and antioxidant potential through the enzymatic activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GSH), alongside serum Zn levels. Our findings revealed that participants had serum Zn concentrations below recommended levels. Supplementation with Zn alongside CoQ10 enhanced the antioxidant efficacy of CoQ10, yielding positive outcomes. This study highlights the prevalence of Zn deficiency in children with DS and suggests that CoQ10 and Zn supplementation may improve antioxidant activity, decrease lipid peroxidation, and preserve antioxidant enzyme function.
- 28 August 2025
- Published by Sociedad Chilena de Nutricion in Revista chilena de nutrición
- Vol. 52 (4) , 192-205
A preliminary study about Coenzyme Q10 and Zinc supplementation in children with Down Syndrome
Down syndrome (DS) is marked by oxidative stress due to an imbalance between reactive oxygen species (ROS) and antioxidant enzymes. Antioxidant compounds like coenzyme Q10 (CoQ10) and zinc (Zn) may mitigate cellular imbalances induced by elevated ROS levels. This double-blind, randomized clinical trial assessed the effects of CoQ10 supplementation, alone and in combination with Zn, in 20 children with DS aged 2–9 years. We evaluated biochemical parameters, dietary intake, anthropometric measures, lipid peroxidation, and antioxidant potential through the enzymatic activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GSH), alongside serum Zn levels. Our findings revealed that participants had serum Zn concentrations below recommended levels. Supplementation with Zn alongside CoQ10 enhanced the antioxidant efficacy of CoQ10, yielding positive outcomes. This study highlights the prevalence of Zn deficiency in children with DS and suggests that CoQ10 and Zn supplementation may improve antioxidant activity, decrease lipid peroxidation, and preserve antioxidant enzyme function.
- Open Access
- 27 May 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (6) , 642
Phytochemical Profiling of Processed Açaí Pulp (Euterpe oleracea) Through Mass Spectrometry and Its Protective Effects Against Oxidative Stress in Cardiomyocytes and Rats
The antioxidant capacity and modulation of oxidative stress by industrially processed açaí pulp extract from the Amazon (APEA) and its major anthocyanins, cyanidin 3-glucoside (C3G) and cyanidin-3-O-rutinoside (C3R), were evaluated as potential strategies for preventing cardiovascular diseases. The APEA was chemically characterized using ultrafast liquid chromatography-mass spectrometry (UFLC-MS), which revealed six main phenolic compounds. Notably, 9-(2,3-dihydroxypropoxy)-9-oxononanoic acid, acanthoside B, roseoside, cinchonine, and nonanedioate were identified for the first time in açaí extracts. In vitro antioxidant assays demonstrated that APEA exhibited strong DPPH- and ABTS-radical-scavenging activities (up to 80% inhibition and 65 mmol TE/100g DW, respectively) and showed ferrous- and copper-ion-chelating activities comparable to those of EDTA-Na2 at higher concentrations (up to 95% inhibition). Hydroxyl and superoxide radical scavenging activities reached 80% inhibition, similar to that of ascorbic acid. In H2O2-treated H9c2 cardiomyocytes, APEA significantly reduced the intracellular ROS levels by 46.9%, comparable to the effect of N-acetylcysteine. APEA also attenuated menadione-induced oxidative stress in H9c2 cells, as shown by a significant reduction in CellROX fluorescence (p < 0.05). In vivo, APEA (100 mg/kg) significantly reduced CCl-induced hepatic lipid peroxidation (MDA levels), restored glutathione (GSH), and increased the antioxidant enzymes CAT, GPx, and SOD, demonstrating superior effects to C3G and C3R, especially after 21 days of treatment (p < 0.001). These findings suggest that Amazonian açaí pulp (APEA) retains potent antioxidant activity after industrial processing, with protective effects against oxidative damage in cardiomyocytes and hepatic tissue, highlighting its potential as a functional food ingredient with cardioprotective and hepatoprotective properties.
- 27 May 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (6) , 642
Open AccessPhytochemical Profiling of Processed Açaí Pulp (Euterpe oleracea) Through Mass Spectrometry and Its Protective Effects Against Oxidative Stress in Cardiomyocytes and Rats
The antioxidant capacity and modulation of oxidative stress by industrially processed açaí pulp extract from the Amazon (APEA) and its major anthocyanins, cyanidin 3-glucoside (C3G) and cyanidin-3-O-rutinoside (C3R), were evaluated as potential strategies for preventing cardiovascular diseases. The APEA was chemically characterized using ultrafast liquid chromatography-mass spectrometry (UFLC-MS), which revealed six main phenolic compounds. Notably, 9-(2,3-dihydroxypropoxy)-9-oxononanoic acid, acanthoside B, roseoside, cinchonine, and nonanedioate were identified for the first time in açaí extracts. In vitro antioxidant assays demonstrated that APEA exhibited strong DPPH- and ABTS-radical-scavenging activities (up to 80% inhibition and 65 mmol TE/100g DW, respectively) and showed ferrous- and copper-ion-chelating activities comparable to those of EDTA-Na2 at higher concentrations (up to 95% inhibition). Hydroxyl and superoxide radical scavenging activities reached 80% inhibition, similar to that of ascorbic acid. In H2O2-treated H9c2 cardiomyocytes, APEA significantly reduced the intracellular ROS levels by 46.9%, comparable to the effect of N-acetylcysteine. APEA also attenuated menadione-induced oxidative stress in H9c2 cells, as shown by a significant reduction in CellROX fluorescence (p < 0.05). In vivo, APEA (100 mg/kg) significantly reduced CCl-induced hepatic lipid peroxidation (MDA levels), restored glutathione (GSH), and increased the antioxidant enzymes CAT, GPx, and SOD, demonstrating superior effects to C3G and C3R, especially after 21 days of treatment (p < 0.001). These findings suggest that Amazonian açaí pulp (APEA) retains potent antioxidant activity after industrial processing, with protective effects against oxidative damage in cardiomyocytes and hepatic tissue, highlighting its potential as a functional food ingredient with cardioprotective and hepatoprotective properties.
- Open Access
In Vitro Antithrombotic, Antitumor and Antiangiogenic Activities of Green Tea Polyphenols and Its Main Constituent Epigallocatechin-3-gallate
The balance between embolic risk and bleeding represents a clinical challenge in cancer patient treatment, encouraging studies on adjuvant oncologic treatments. Thereby, this study evaluated the in vitro effect of green tea extract (GTE) and epigallocatechin-3-gallate (EGCG) on hemostasis modulation and the antineoplastic effect on melanoma cells (B16-F10) by applying platelet aggregation, angiogenesis and viability cell assays. The results displayed a significant platelet antiaggregant effect, corresponding to 50 and 80% for the extract and EGCG, respectively, compared to the negative control. Furthermore, both GTE and EGCG exhibited antitumor effects by reducing melanoma cell growth by 25 and 50%, respectively, verified by cellular apoptosis. Regarding angiogenesis, these substances inhibited blood vessel formation, reaching about 25% and 99% for GTE and EGCG at 100 μg/mL, respectively. Moreover, TNF-α cell stimulation evidenced VEGF and IL-8 secretion inhibition at 55 and 20% with GTE, while EGCG promoted an inhibition around 78% for both VEGF and IL-8. The results indicate the promising performance of GTE and EGCG as an option for treating cancer and its side effects. Nonetheless, further studies are required to elucidate their action mechanism on clotting, cell death and angiogenesis.
Open AccessIn Vitro Antithrombotic, Antitumor and Antiangiogenic Activities of Green Tea Polyphenols and Its Main Constituent Epigallocatechin-3-gallate
The balance between embolic risk and bleeding represents a clinical challenge in cancer patient treatment, encouraging studies on adjuvant oncologic treatments. Thereby, this study evaluated the in vitro effect of green tea extract (GTE) and epigallocatechin-3-gallate (EGCG) on hemostasis modulation and the antineoplastic effect on melanoma cells (B16-F10) by applying platelet aggregation, angiogenesis and viability cell assays. The results displayed a significant platelet antiaggregant effect, corresponding to 50 and 80% for the extract and EGCG, respectively, compared to the negative control. Furthermore, both GTE and EGCG exhibited antitumor effects by reducing melanoma cell growth by 25 and 50%, respectively, verified by cellular apoptosis. Regarding angiogenesis, these substances inhibited blood vessel formation, reaching about 25% and 99% for GTE and EGCG at 100 μg/mL, respectively. Moreover, TNF-α cell stimulation evidenced VEGF and IL-8 secretion inhibition at 55 and 20% with GTE, while EGCG promoted an inhibition around 78% for both VEGF and IL-8. The results indicate the promising performance of GTE and EGCG as an option for treating cancer and its side effects. Nonetheless, further studies are required to elucidate their action mechanism on clotting, cell death and angiogenesis.